

Receipt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Barry G. Hall)
Serial No : 09/640,882)
Cnfrm No : 6458)
Filed : August 18, 2000)
For : METHOD OF DETERMINING)
EVOLUTIONARY POTENTIAL OF)
MUTANT RESISTANCE GENES AND)
USE THEREOF TO SCREEN FOR DRUG)
EFFICACY)
)

RECEIVED

SEP 12 2001

TECH CENTER 1600/2900

THIRD REQUEST FOR CORRECTED FILING RECEIPT

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

Dear Sir:

Applicant hereby requests a third corrected filing receipt for the above-identified application. On the enclosed copy of the official filing receipt, the Domestic Priority data as claimed by applicant reads "THIS APPLN CLAIMS BENEFIT OF 60/146,813 08/02/1999" but should read "THIS APPLN CLAIMS BENEFIT OF 60/149,813 08/19/1999". A copy of the signed combined declaration and power of attorney as filed showing the correct priority data is enclosed herewith.

Since Applicant is not responsible for these errors, no fee is enclosed.

Respectfully submitted,


Edwin V. Merkel
Registration No. 40,087

Dated: May 7, 2001


Nixon Peabody LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (716) 263-1128
Facsimile: (716) 263-1600

Certificate of Mailing - 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below.

5/7/01
Date

Jane C. Wirszyk

**RECEIVED**

Page 1 of 4

SEP 12 2001

TECH CENTER 1600/2900

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/640,882	08/18/2000	1644	0.00	176/60851 (1-11027-849)	15	63	6

CONFIRMATION NO. 6458**FILING RECEIPT**

Michael L Goldman
Nixon Peabody LLP
Clinton Square
PO Box 31051
Rochester, NY 14603



OC000000006020054

Date Mailed: 04/30/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Barry G. Hall, Rochester, NY;

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/149,813 08/02/1999

9 19

60/149,813

8/19/1999

Foreign Applications

If Required, Foreign Filing License Granted 10/03/2000

Projected Publication Date: N/A

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Method of determining evolutionary potential of mutant resistance genes and use thereof to screen for drug efficacy

Preliminary Class

530

Data entry by : DADE, JOAN

Team : OIPE

Date: 04/30/2001



RECEIVED

SEP 12 2001

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15 TECH CENTER 1600/2900**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

FILE COPY



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 6458

SERIAL NUMBER 09/640,882	FILING DATE 08/18/2000 RULE	CLASS 424	GROUP ART UNIT 1645	ATTORNEY DOCKET NO. 176/60851(1-11027-849)
-----------------------------	-----------------------------------	--------------	------------------------	--

APPLICANTS

Barry G. Hall, Rochester, NY;

RECEIVED

SEP 12 2001

TECH CENTER 1600/2900

** CONTINUING DATA *****

THIS APPLN CLAIMS BENEFIT OF 60/149,813 08/19/1999

** FOREIGN APPLICATIONS *****

IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** SMALL ENTITY **
 ** 10/03/2000

Foreign Priority claimed	<input type="checkbox"/> yes <input type="checkbox"/> no	STATE OR COUNTRY NY	SHEETS DRAWING 15	TOTAL CLAIMS 63	INDEPENDENT CLAIMS 6
35 USC 119 (a-d) conditions met	<input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance				
Verified and Acknowledged	Examiner's Signature	Initials			

ADDRESS

Michael L Goldman
 Nixon Peabody LLP
 Clinton Square
 PO Box 31051
 Rochester ,NY 14603

TITLE

Method of determining evolutionary potential of mutant resistance genes and use thereof to screen for drug efficacy

FILING FEE RECEIVED 914	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit
----------------------------	---	---